Financing resistance | Why new investors are urgently needed and where they come from
Moderator: Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
Speakers:
- Thomas Cueni – Director General, IFPMA
This content has been restricted to logged in users only. Please login to view this content.
- James Anderson – Head of Corporate Government Affairs, GSK
- Silas Holland – Head of External Affairs for the AMR Action Fund & Director for Global Public Policy MSD
This content has been restricted to logged in users only. Please login to view this content.
- Deborah A O’Neil – CEO, NovaBiotics Ltd & Board Member, BEAM Alliance
This content has been restricted to logged in users only. Please login to view this content.
- Aleks Engel – Partner, Novo Holdings (Novo Seeds) & Director, REPAIR Impact Fund at Novo Holdings
This content has been restricted to logged in users only. Please login to view this content.
Play Video
This might also be of interest for you:
- All background information about the AMR Action Fund can be found here
- European Biotechnology News, 13 July: AMR: Big Pharma sets up US$1bn Fund
- BEAM Alliance and REPAIR Impact Fund at Novo Holdings in the AMR Stakeholder Guide
